Pauline Rochefort

Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception

Mylène Wespiser, Pauline Rochefort, Thibault Gauduchon, Clio Coste et autres

fr (code pays fourni par la source)

Cancer risks for ATM variant heterozygotes

Yue Jiao, David E Goldgar, Dorothée Le Gal, Eve Cavaciuti et autres

fr, us (code pays fourni par la source)

Cancer risks in Lynch syndrome carriers: a systematic review and meta-analysis

Séphora Campoy, Youenn Drouet, Pauline Rochefort, Valérie Bonadona et autres

BACKGROUND: Lynch syndrome (LS), caused by pathogenic variants (PVs) in mismatch repair genes, increases the risk of several cancers. Surveillance guidelines vary internationally due to inconsistent risk estimates. This study refines cancer risk estimates by gene, sex, and age to support personalized …

fr (code pays fourni par la source)

159eP Automatic generation of lay-friendly molecular tumor board reports using large language models: A feasibility study

Stacia Aho, M. Beaudéant, Célia Lelong, H. Crochet et autres

fr (code pays fourni par la source)

Abstract PS16-04: Differences in breast cancer phenotype by germline TP53 variant functional classification

Renata Lazari Sandoval, Michele Bottosso, Miki Horiguchi, Natália Polidorio et autres

Abstract Introduction: TP53 is a multi-functional tumor suppressor gene, with several important roles in tumorigenesis. Females who harbor germline TP53 pathogenic/likely pathogenic variants (GPV) have a very high lifetime risk of developing breast cancer (BC), especially hormone receptor positive and HER2 positive …

Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial

Sheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, Méher Ben Abdelghani et autres

BACKGROUND: Retifanlimab has activity in programmed death ligand 1-positive advanced squamous cell anal carcinoma (SCAC) that has progressed on platinum chemotherapy. We aimed to prospectively assess the benefit of adding retifanlimab to initial carboplatin-paclitaxel for this disease. METHODS: This global, multicentre, double-blind, …

gb, fr, it, au, es, us (code pays fourni par la source)

Experience of patients with HIV and squamous cell carcinoma of the anal canal (SCAC) treated with retifanlimab.

Jean‐Philippe Spano, Jaume Capdevila, Frank Van Fraeyenhove, Sara Lonardi et autres

3521 Background: People living with HIV (PLHIV) usually have more advanced cancer at diagnosis and a higher cancer-related mortality, posing a significant burden on health care. However, clinical studies often exclude cancer patients with HIV, thereby limiting access to therapies for this …

fr, es, be, it, gb, us (code pays fourni par la source)

Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy

François Poumeaud, Thibaud Valentin, Nadim Farés, Bertille Segier et autres

fr (code pays fourni par la source)

LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)

Sheela Rao, E. Samalin-Scalzi, Ludovic Evesque, Méher Ben Abdelghani et autres

gb, fr, it, au, es, us (code pays fourni par la source)

Information and prevention needs among germline TP53(gTP53m)pathogenic variants carriers.

Tarek Ben Ahmed, Pauline Vidican, Nadège Corradini, Christine Lasset et autres

10551 Background: Li-Fraumeni syndrome (LFS) and more generally g TP53m situations increase the risk of many malignancies. A modifier role of several attributable factors has been recently suggested on LFS-carcinogenesis, including reproductive and lifestyle factors, obesity, physical activity (PA) and diet. However, …

fr (code pays fourni par la source)

Gastrectomies prophylactiques

Perrine Côme, Pauline Rochefort, Lucas De Crignis, Aurélien Dupré

One to 3% of gastric cancers are secondary to genetic predisposition, notably hereditary diffuse gastric cancers (HDGC) caused by CDH1 gene mutations. According to French recommendations, in case of CDH1 gene mutation, a prophylactic total gastrectomy should be performed between 20 and …

fr (code pays fourni par la source)

1684TiP PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer

Philippe Alexandre Cassier, Claire Cropet, Clélia Coutzac, Pauline Rochefort et autres

fr (code pays fourni par la source)